Comparison of the effects of heparin and enoxaparin in the occurrence of venous thromboembolism after abdominal surgery in operated patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240923063130N1

Enrollment

116

Registered

2024-11-14

Start date

2024-10-26

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism. Pulmonary embolism

Interventions

Intervention 1: Intervention group: at the end of the operation of group one, N=58 heparin is injected subcutaneously in the amount of 5000 units and is repeated within 24 to 48 hours. Intervention 2:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent abdominal surgery in the hospitals of Islamic Azad University of Tehran during 2024 receiving heparin and enoxaparin thromboprophylaxis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The occurrence of thromboembolism, age, gender, number of hospitalization days, drug complications. Timepoint: The sampling method was simple random sampling, and participants were assigned to case and control groups using a random number table or a lottery. The first group was the case or test group (receiving enoxaparin), and the second group was the control group (receiving heparin). Method of measurement: According to a study, the sample size is calculated based on the reported incidence of venous thromboembolism, with 14% for the enoxaparin group and 18% for the placebo group, and it will be determined for the group receiving heparin.	—

Measure

Time frame

The occurrence of thromboembolism, age, gender, number of hospitalization days, drug complications. Timepoint: The sampling method was simple random sampling, and participants were assigned to case and control groups using a random number table or a lottery. The first group was the case or test group (receiving enoxaparin), and the second group was the control group (receiving heparin). Method of measurement: According to a study, the sample size is calculated based on the reported incidence of venous thromboembolism, with 14% for the enoxaparin group and 18% for the placebo group, and it will be determined for the group receiving heparin.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHeydar Darvish

Islamic Azad University

Hdarvishi@iauimuic.ir+98 21 5534 6552

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026